Diabetes Research Study Evaluating a New Approach To Helping Patients Now Offered in Warwick

Adults with type 2 diabetes and weight problems may have the opportunity to join a clinical study on an investigational procedure to lower blood sugar levels without taking insulin.

A new diabetes research study is available in Warwick, R.I., to evaluate a non-drug procedure that may help improve blood sugar without increasing medicines or insulin.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240226550152/en/

“The effective management of type 2 diabetes is crucial for preventing cardiovascular disease and other serious conditions, especially among patients with high BMI,” said Dr. Sudhir Bansal, Principal Investigator at Care Access - Warwick. (Photo: Business Wire)

“The effective management of type 2 diabetes is crucial for preventing cardiovascular disease and other serious conditions, especially among patients with high BMI,” said Dr. Sudhir Bansal, Principal Investigator at Care Access - Warwick. (Photo: Business Wire)

The combination of diabetes and obesity significantly increases one’s risk of heart attacks, stroke, liver disease, kidney disease, and other serious health problems. Current treatments that aim to lower blood sugar to a healthy level are unsuccessful for many patients, but medical researchers are discovering new potential ways to help people with type 2 diabetes.

The REVITALIZE 1 study from Fractyl Health will assess if an investigational procedure known as duodenal mucosal resurfacing (DMR) can help address a range of health problems caused by diabetes. The DMR procedure targets the inner lining of the duodenum (a portion of the small intestine) and uses heat to remove the thickened or diseased lining so the body can regrow a new, healthy lining capable of potentially helping to control blood glucose, improve insulin resistance, and improve control of diabetes without needing to take more medicines or insulin.

“The effective management of type 2 diabetes is crucial for preventing cardiovascular disease and other serious conditions, especially among patients with high BMI,” said Dr. Sudhir Bansal, Principal Investigator at Care Access - Warwick. “The medical community is working very hard to find new treatment options to help these patients, and this research study is an important step towards that goal.”

The study is now enrolling for adults ages 21 to 70 with type 2 diabetes and BMI of 24 to 40 kg/m2. To learn more, contact Care Access at (351) 222-5112.

Care Access opened its doors in Warwick in collaboration with local community leaders and healthcare providers seeking to make clinical studies more easily accessible to patients. The local setting provides residents of Warwick and surrounding communities the option to participate in clinical studies close to home.

About Care Access

Care Access is a global clinical research company helping to accelerate the future of medicine. With a global network of over 200 research sites, Care Access supports research studies conducted by 14 of the top 15 biopharmaceutical companies. In addition to its proven track record of globally top-enrolling sites, Care Access partners with new-to-research communities and establishes high-quality research site infrastructure locally to expand access to clinical trials and increase representation.

For research sponsors, Care Access offers three core services: (1) global network of research sites, (2) community screenings to expand a study’s reach, and (3) on-demand staffing, space expansion, and training services to support all research sites on a study.

To learn more about active studies at Care Access, or how Care Access helps sponsors achieve enrollment and representation goals, visit www.careaccess.com.

“The effective management of type 2 diabetes is crucial for preventing cardiovascular disease and other serious conditions, especially among patients with high BMI,” said Dr. Sudhir Bansal, Principal Investigator at Care Access - Warwick. #clinicaltrial

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.